Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - Smith, J A; Kitt, M M; Morice, A H (Lancet Resp Med, 2020)
et al.